[Translation] A randomized, open-label, two-sequence, four-period, completely repeated crossover bioequivalence study of carbodopa extended-release tablets in Chinese healthy subjects under fasting and fed conditions

主要研究目的研究空腹和餐后状态下单次口服卡左双多巴缓释片（卡比多巴50mg，左旋多巴200mg，江苏和晨药业有限公司提供）与参比制剂（卡比多巴50mg，左旋多巴200mg，息宁®；持证商：MSD Sharp & Dohme GmbH）后卡比多巴、左旋多巴在中国健康受试者体内的药代动力学（PK）特征，评价空腹和餐后状态下口服两种制剂的生物等效性。次要研究目的评价中国健康受试者空腹和餐后状态下，单次口服受试制剂卡左双多巴缓释片和参比制剂卡左双多巴缓释片后的安全性。

[Translation]

Main study objectives To study the pharmacokinetic (PK) characteristics of carbidopa and levodopa in healthy Chinese subjects after a single oral administration of carbidopa 50 mg, levodopa 200 mg, provided by Jiangsu Hechen Pharmaceutical Co., Ltd. and reference preparation (carbidopa 50 mg, levodopa 200 mg, Xining®; licensee: MSD Sharp & Dohme GmbH) in fasting and fed states, and to evaluate the bioequivalence of the two preparations in fasting and fed states. Secondary study objectives To evaluate the safety of the test preparation carbidopa 50 mg and reference preparation carbidopa 50 mg after a single oral administration in fasting and fed states in healthy Chinese subjects.

Start Date13 Apr 2024

Sponsor / Collaborator

Jiangsu Hechen Pharmaceutical Co., Ltd.

NCT06219915 / CompletedPhase 1/2IIT

Neurobiological Drivers of Mobility Resilience: The Dopaminergic System

Walking with age becomes both slower and less 'automated', requiring more attention and brain resources. As a result, older adults have a greater risk of negative outcomes and falls. There is an urgent need to identify factors that can help compensate for these harmful factors and reduce walking impairments, as there are currently no effective treatments available. Investigators have recently discovered that
20% of older adults maintain fast walking speed even in the presence of small blood vessel brain changes and leg problems, thus appearing to be protected against these harmful factors. The investigators work suggests that the brain dopamine (DA) system may be a source of this protective capacity. Investigators have also shown that lower levels of dopamine are associated with slow walking. Investigators will be investigating the role of dopamine on slow walking and other parkinsonian signs in this double-blinded, placebo-controlled study using detailed clinical assessment, assessment of dopamine activity, and clinical interventions.

Start Date15 Mar 2024

Sponsor / Collaborator

University of Michigan

[+1]

NCT05285683 / RecruitingPhase 2IIT

The Role of Dopamine in the Central Neural Signature of Chronic Pain

Chronic pain is associated with plasticity in the brain limbic system composed mainly of the amygdala, hippocampus, ventral striatum, and cingulate cortex (ACC) /medial prefrontal cortex (mPFC). These brain areas, especially the ventral striatum, receive dopaminergic input from the ventral-tegmental area (VTA). Although there is a significant literature now showing that limbic brain tracks chronic pain intensity and predicts the risk of transition from sub-acute to chronic pain, the role of dopaminergic input to the limbic brain and the change thereof which occurs in chronic pain, is still not clear.
Given the role of dopamine in motivational control and the loss of motivation associated with chronic pain understanding how dopaminergic transmission is altered in the limbic brain of chronic pain patients is critical to the understanding of the pathophysiology of chronic pain. Therefore, the overall aim of this project is to use brain imaging to study how dopaminergic transmission through the oral administration of pro-dopaminergic medications carbidopa/levodopa (CD/LD) and methylphenidate will modulate the brain signature of chronic pain. Chronic pain subjects will be scanned twice before and after treatment with the two drugs or placebo. The protocol will follow a randomized double-blind approach.

Start Date02 Feb 2024

Sponsor / Collaborator

University of Rochester

100 Clinical Results associated with Carbidopa/Levodopa

100 Translational Medicine associated with Carbidopa/Levodopa

100 Patents (Medical) associated with Carbidopa/Levodopa

729

Literatures (Medical) associated with Carbidopa/Levodopa

01 Feb 2024·Journal of the neurological sciences

Optimization of oral entacapone administration in patients undergoing levodopa–carbidopa intestinal gel treatment

Article

Author: Tada, Satoshi ; Ando, Rina ; Yabe, Hayato ; Nagai, Masahiro ; Yamanishi, Yuki ; Miyaue, Noriyuki ; Ito, Yuko

BACKGROUND:

Levodopa-carbidopa intestinal gel (LCIG) treatment markedly reduces motor fluctuations in patients with Parkinson's disease; however, some patients undergoing LCIG treatment may demonstrate clinical deterioration in the afternoon. Entacapone, a catechol-O-methyltransferase inhibitor, may be a promising adjunctive option for LCIG-treated patients; however, the optimal timing of oral entacapone administration to ameliorate clinical symptoms in the afternoon remains unexplored. This study aimed to investigate the optimal timing of oral entacapone administration in patients with Parkinson's disease undergoing LCIG treatment.

METHODS:

Pharmacokinetic analysis and symptom assessment were performed on three days: a day without entacapone administration, day with oral entacapone administration at 13:00, and day with oral entacapone administration at 15:00.

RESULTS:

Eight LCIG-treated patients were enrolled, of whom seven completed this study. The relative plasma concentrations of levodopa with entacapone administration at 13:00 were gradually increased, especially at 18:00 and were significantly higher than those without entacapone administration (127.10 ± 25.06% vs. 97.51 ± 22.20%). The relative plasma concentrations of 3-O-methyldopa were gradually increased without entacapone administration, whereas those with entacapone administration at 13:00 were lower than those without entacapone administration, especially at 17:00 (97.47 ± 3.70% vs. 110.71 ± 9.84%). Administering oral entacapone at 15:00 increased and decreased the relative plasma concentrations of levodopa and 3-O-methyldopa, respectively, but without significant difference. The "Off" time was shorter with entacapone administration at 13:00 (0.43 ± 0.79 h) and at 15:00 (0.57 ± 0.79 h) than that without entacapone administration (1.14 ± 1.46 h).

CONCLUSIONS:

The concomitant use of oral entacapone in the early afternoon may be effective in improving afternoon symptoms in patients undergoing LCIG treatment.

01 Feb 2024·Pharmacology research & perspectives

Decreased hepatic enzymes reflect the decreased vitamin B6 levels in Parkinson's disease patients

Article

Author: Wang, Nan ; Aguirre, César ; Taniguchi, Seira ; Ogawa, Kotaro ; Choong, Chi-Jing ; Kakuda, Keita ; Mochizuki, Hideki ; Doi, Junko ; Kimura, Yasuyoshi ; Kajiyama, Yuta ; Ikenaka, Kensuke ; Ajiki, Takahiro

Abstract:

The study aims to investigate the vitamin B6 levels in Parkinson's disease (PD) patients and their association with liver enzymes and evaluate how much dysregulation is associated with levodopa dose. Furthermore, to evaluate the effect of Opicapone, a catechol‐o‐methyl‐transferase inhibitor, on vitamin B6 levels by monitoring the AST and ALT levels in patients treated with Levodopa–Carbidopa Intestinal Gel Infusion (LCIG). For these aims, serum vitamin B6 levels were measured (PD, n = 72 and controls, n = 31). The vitamin B6 level was compared with the total levodopa dose, clinical parameters, and blood homocysteine, albumin, and hemoglobin levels in PD patients. Correlations between vitamin B6 levels and AST and ALT levels, as well as the ratio ALT/AST, were analyzed. Changes in the AST and ALT levels and ALT/AST were analyzed in the patients treated with LCIG before and after the therapy (n = 24) and in the patients treated with LCIG + Opicapone before and after Opicapone treatment (n = 12). We found vitamin B6 levels were significantly lower in PD patients. Total levodopa dose and albumin levels were independently associated with vitamin B6 levels. Decreased vitamin B6 levels appeared as lower AST and ALT levels and ALT/AS. Treatment with LCIG decreased the AST and ALT levels and ALT/AST. Adjunctive therapy with Opicapone to LCIG ameliorated the decreased ALT and ALT/AST. We conclude that the ALT and ALT/AST can be useful parameters for monitoring vitamin B6 levels and Opicapone can ameliorate the dysregulated vitamin B6 in PD patients.

01 Jan 2024·Rinsho shinkeigaku = Clinical neurology

A 70-year-old male exhibiting parkinsonism-hyperpyrexia syndrome during levodopa carbidopa intestinal gel (LCIG) treatment and suspected carbidopa allergy due to positive drug-induced lymphocyte stimulation test (DLST)

Article

Author: Miyashita, Masanobu ; Kawanami, Aya ; Miyagi, Yuichi ; Hasegawa, Kazuko

A 70-year-old male who has medical history of Parkinson's disease for 26 years admitted to our hospital for trial of levodopa carbidopa intestinal gel (LCIG) therapy because of severe dyskinesia and frequent wearing-off. He developed deterioration when he was treated with one of the levodopa (LD) decacrboxylase inhibitor compounds in the past. Five days after LD had changed into equivalent dose of LD/carbidopa (CD), high fever with hyperCKemia appeared. He was diagnosed as having Parkinsonism-hyperpyrexia syndrome (PHS). Exchange of LD/CD to LD drugs improved the symptoms quickly. Four days after LCIG administration, PHS reappeared. Simultaneously, the patient developed sepsis and disseminated intravascular coagulation (DIC). Thrombocytopenia did not improve after recovery from infection and DIC. Anti-PA IgG and drug-induced lymphocyte stimulation test (DLST) against LCIG showed positive. Exchange of LCIG to LD drugs and intravenous methylprednisolone administration improved the symptoms and thrombocytopenia. CD induced type II and type IV allergy were suspected. This case offers a caution that physicians should be aware of drug allergy in cases of which unexpected symptoms occurred in altering one LD compound to another.

News (Medical) associated with Carbidopa/Levodopa

16 May 2024

·www.prnewswire.com

Mitsubishi Tanabe Pharma America Announces Presentations at XXIX World Congress on Parkinson's Disease and Related Disorders

JERSEY CITY, N.J., May 16, 2024 /PRNewswire/ -- Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced two presentations on investigational ND0612 in Parkinson's disease (PD) will be shared at the International Association of Parkinsonism and Related Disorders (IAPRD) XXIX World Congress on Parkinson's Disease and Related Disorders, being held in Lisbon, Portugal, May 19-22. "We are eager to discuss the latest findings from our ongoing Phase 3 BouNDless and Phase 2b BeyoND clinical trials evaluating the efficacy and safety of investigational ND0612 in people with Parkinson's disease experiencing motor fluctuations," said Gustavo A. Suarez Zambrano, M.D., Vice President of Medical Affairs, MTPA. "Our presence at IAPRD this year exemplifies our determination to continue exploring how to address the challenges faced by people living with this disease, including the impact of motor fluctuations." MTPA's posters will be presented during Oral Poster Sessions at the meeting on May 21, 2024 at 9:35 a.m. – 10:20 a.m. WEST. Presentation Details: Presentations include results from the pivotal Phase 3 multi-center, randomized, double-blind double-dummy BouNDless trial (NCT04006210) evaluating the efficacy, safety and tolerability of investigational ND0612 in people with PD experiencing motor fluctuations, in addition to three-year outcomes from the Phase 2b open-label BeyoND study (NCT02726386) evaluating the long-term safety of ND0612 in reducing OFF time in people with PD. Continuous subcutaneous levodopa/carbidopa infusion (ND0612) for patients with Parkinson's disease and motor fluctuations: A Phase 3, active-controlled BouNDless stud y (Fabrizio Stocchi, M.D., Ph.D., Institute for Research and Medical Care (IRCCS), San Raffaele, Rome) Oral Poster #O_42 Continuous subcutaneous levodopa/carbidopa infusion with ND0612 for Parkinson's disease: Three-year data from the open-label BeyoND study (Fabrizio Stocchi, M.D., Ph.D., University San Raffaele Roma and IRCCS San Raffaele) Oral Poster #O_41 About ND0612 ND0612 is an investigational drug-device combination therapy – a 24-hours/day, continuous subcutaneous (SC) infusion of liquid levodopa/carbidopa (LD/CD) for the treatment of motor fluctuations in people with Parkinson's disease (PD). Development of investigational ND0612 is being led by NeuroDerm, Ltd., a wholly-owned subsidiary of Mitsubishi Tanabe Pharma Corporation (MTPC). About Mitsubishi Tanabe Pharma America, Inc. Based in Jersey City, N.J., Mitsubishi Tanabe Pharma America, Inc. (MTPA) is a wholly-owned subsidiary of Mitsubishi Tanabe Pharma Corporation (MTPC). It was established by MTPC to develop and advance our pipeline as well as commercialize approved pharmaceutical products in North America. For more information, please visit or follow us on X (formerly Twitter), Facebook and LinkedIn. About Mitsubishi Tanabe Pharma Corporation Mitsubishi Tanabe Pharma Corporation (MTPC), the pharma arm of Mitsubishi Chemical Group (MCG), is one of the oldest pharmaceutical companies in the world, founded in 1678. MTPC is headquartered in Doshomachi, Osaka, the birthplace of Japan's pharmaceutical industry. MCG has positioned health care as its strategic focus in its management policy, "Forging the future". MTPC sets the MISSION of "Creating hope for all facing illness". To that end, MTPC is working on the disease areas of central nervous system, immuno-inflammation, diabetes and kidney, and cancer. MTPC is focusing on "precision medicine" to provide drugs with high treatment satisfaction and additionally working to develop "around the pill solutions" to address specific patient concerns based on therapeutic medicine, including prevention of diseases, pre-symptomatic disease care, prevention of aggravation and prognosis. For more information, go to . About NeuroDerm, Ltd. NeuroDerm, Ltd. is a wholly-owned subsidiary of Mitsubishi Tanabe Pharma Corporation (MTPC), based in Israel, inspired to reduce disease burden and improve the quality of life of patients and their families through innovative drug-device combination therapies and technologies. NeuroDerm is an integrated pharmaceutical and medical technology company developing central nervous system (CNS) product candidates. For additional information, please visit NeuroDerm's website at  or follow the Company on LinkedIn. Media inquiries: [email protected] SOURCE Mitsubishi Tanabe Pharma America

Phase 2Phase 3

22 Apr 2024

·www.biospace.com

AbbVie, NeuroDerm Heat Up Levodopa Competition with New Data at AAN24

Pictured: Doctor looking at a patient's brain scans/iStock, Shidlovski With potential U.S. approvals on the line in Parkinson’s disease later this year, AbbVie and NeuroDerm presented promising data for their respective continuous, subcutaneous levodopa infusions at last week’s American Academy of Neurology 2024 annual meeting. Both companies are developing novel delivery systems that allow 24-hour continuous subcutaneous delivery of their drug candidates, which according to Erela Dana, director of neurology at data analytics firm Global Data, could “improve the rate of compliance while reducing risk of motor fluctuations and levodopa-induced complications.” At AAN24, AbbVie showed that its investigational subcutaneous treatment foslevodopa/foscarbidopa could elicit significant improvement in “on” time without troublesome dyskinesia in patients younger than 65 years of age. In Parkinson’s disease, on time refers to periods of good symptom control. However, in those aged 65 years and older, the effect of foslevodopa/foscarbidopa was “numerical” and failed to reach statistical significance, according to AbbVie’s AAN24 abstract. In all other patient subgroups, foslevodopa/foscarbidopa also led to “numerical improvements” in on time without troublesome dyskinesia and “off” time, which refers are the periods when symptoms grow more noticeable and difficult to manage. According to GlobalData, AbbVie also presented long-term safety and tolerability data for foslevodopa/foscarbidopa from an open-label study. Results showed that nearly 84% of treated patients developed at least one adverse event, the most common of which were infusion site erythema and cellulitis. “The success of levodopa infusion systems requires avoidance of infusion-site reactions and reduced discontinuation rates due to safety and tolerability issues,” Dana said, adding that AbbVie’s data “addresses some of these concerns.” AbbVie is developing foslevodopa/foscarbidopa—a combination of prodrugs of levodopa and carbidopa, respectively—for the treatment of motor disturbances in adult patients with advanced Parkinson’s disease. In March 2023, the FDA hit the drug candidate with a Complete Response Letter, requesting additional information regarding its pump system. AbbVie at the time said it planned to resubmit the application. At AAN24, NeuroDerm also presented data from a subgroup analysis of its Parkinson’s disease candidate ND0612, which improved on time without troublesome dyskinesia and had an “overall homogenous” effect when disaggregating patients according to age, sex, baseline disease severity and other factors. Overall, ND0612 was able to improve on time without troublesome dyskinesia by 1.72 hours, according to NeuroDerm’s AAN24 abstract. ND0612 is a drug-device combination therapy that allows the continuous infusion of a levodopa/carbidopa mixture. The investigational product is being developed to treat motor fluctuations in Parkinson’s disease and has a target action date in the second quarter of 2024. While NeuroDerm could beat AbbVie in the race to U.S. commercialization, Dana notes that if both products receive FDA approval real-world evidence and longer-term follow-up data “could provide a competitive edge in the absence of a head-to-head trial.” Tristan Manalac is an independent science writer based in Metro Manila, Philippines. Reach out to him on LinkedIn or email him at tristan@tristanmanalac.com or tristan.manalac@biospace.com.

Clinical Result

18 Apr 2024

·www.fiercebiotech.com

AbbVie-bound Cerevel reports phase 3 Parkinson's victory in early win for $8.7B deal

Mizuho Securities analysts model peak annual U.S. sales of tavapadon of $532 million. The backing singer in AbbVie’s $8.7 billion takeover of Cerevel Therapeutics is having its moment in the spotlight. Cerevel thrust tavapadon to the fore Thursday, reporting the success of a phase 3 Parkinson’s disease trial and providing a small boost to AbbVie as it works to close a deal focused on another asset. Emraclidine, Cerevel’s midphase schizophrenia prospect, was the headline act when AbbVie disclosed the deal to buy the biotech late last year but tavapadon represents the first chance to start generating a return on the outlay. Tavapadon is a once-daily oral dopamine D1/D5 receptor partial agonist that is designed to balance meaningful motor control activity with a favorable tolerability profile. On Thursday, Cerevel provided the strongest evidence yet that the molecule strikes that balance. The data come from a phase 3 trial that randomized 507 adults with Parkinson’s and motor fluctuations. Subjects had to be on a stable dose of levodopa for at least four weeks prior to screening and continued to take the drug in combination with tavapadon or placebo once the trial began. Over the 27-week trial, patients who took tavapadon spent significantly more time without troublesome uncontrolled, involuntary movements, known medically as dyskinesia, than their peers on placebo. The study, which collected data using a self-completed home diary for motor function status, showed people on the drug spent 1.7 hours without troublesome dyskinesia, compared to 0.6 hours in the control arm. Cerevel also reported a significant reduction in the time patients had symptoms but is yet to share data on that secondary endpoint. Similarly, the biotech said the molecule was generally well tolerated, with no surprises and most adverse events being mild or moderate, but is holding off on providing a closer look at the safety data until medical meetings. The meetings are part of a roadmap of updates on tavapadon that includes regulatory submissions and topline results from a pair of phase 3 studies that are testing the molecule as a monotherapy. Cerevel expects to share data from the other phase 3 trials in the second half of the year, by when AbbVie intends to close the acquisition. Jeffrey Stewart, chief commercial officer at AbbVie, discussed tavapadon on a call with investors when the drugmaker announced the Cerevel takeover. AbbVie already has a presence in advanced Parkinson’s, with Duopa and is developing ABBV-951, but is absent from the earlier, oral segment targeted by tavapadon. “Tavapadon ... could be a nice complementary product up in the more early phases of the condition, so distinct from where we play now, but also complementary in terms of our commercial infrastructure. We believe it's relatively modest—the bulk of the value does sit on emraclidine—but nonetheless a nice fit to where we can slot that in with our global teams across the world,” Stewart said. Mizuho Securities analysts model peak annual U.S. sales of $532 million, making it a “relatively small revenue contributor” in the context of Cerevel’s wider pipeline. That fact, coupled with the fact AbbVie is already set to buy the biotech, led the analysts to predict the data will have “very little material impact to the current [Cerevel] investment narrative” in a note to investors.

Phase 3AcquisitionClinical Result

100 Deals associated with Carbidopa/Levodopa

External Link

KEGG	Wiki	ATC	Drug Bank
-	Carbidopa/Levodopa	N04BA02	-

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Parkinsonian Disorders	JP	Tatsumi Kagaku Co., Ltd.	14 May 1993
Parkinson Disease	US	Organon & Co.	02 May 1975
Parkinson Disease, Postencephalitic	US	Organon & Co.	02 May 1975
Parkinson Disease, Secondary	US	Organon & Co.	02 May 1975

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Dyskinesias	Phase 3	US	AbbVie, Inc.	09 Feb 2017
Dyskinesias	Phase 3	FI	AbbVie, Inc.	09 Feb 2017
Dyskinesias	Phase 3	GR	AbbVie, Inc.	09 Feb 2017
Dyskinesias	Phase 3	HU	AbbVie, Inc.	09 Feb 2017
Dyskinesias	Phase 3	IT	AbbVie, Inc.	09 Feb 2017
Dyskinesias	Phase 3	SK	AbbVie, Inc.	09 Feb 2017
Dyskinesias	Phase 3	ES	AbbVie, Inc.	09 Feb 2017
Complication	Phase 3	-	AbbVie, Inc.	01 Oct 2013
Psychomotor Agitation	Phase 3	US	AbbVie, Inc.	01 Jun 2009
Psychomotor Agitation	Phase 3	DE	AbbVie, Inc.	01 Jun 2009

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04006210 (BouNDless, Literature) Manual	Phase 3	Parkinson Disease	381	ND0612	snaoecrzzf(sxmmqjewhs) = pvlnljuikv usqaegntlm (egdgyytizo, –0.94 ~ –0.02) Met View more	Positive	15 Mar 2024
				levodopa+carbidopa	snaoecrzzf(sxmmqjewhs) = mwkrrdfkjy usqaegntlm (egdgyytizo, –2.65 ~ –1.74) Met View more
NCT04196647 (NCT4196647, Pubmed)	Not Applicable	Parkinson Disease	12	Home-Based Titration with LCIG	mgfdownsel(sniledlfhh) = nbbqgtyzxx tfyjqyihpe (oxvluakskl, 2 - 5) View more	Positive	01 Jan 2024
NCT03781167 (CTgov)	Phase 3	Parkinson Disease	244	ABBV-951 (ABBV-951 Low Dose Subgroup)	yuwtessmor(vuuvibzczw) = evpcgibsty neafitkukr (tcfbtrptkd, aburynljil - tkmvxdaiai) View more	-	23 Oct 2023
				ABBV-951 (ABBV-951 High Dose Subgroup)	yuwtessmor(vuuvibzczw) = prmssjxksq neafitkukr (tcfbtrptkd, wtygfohpuv - quxyhkirka) View more
NCT04006210 (BouNDless, PRNewswire) Manual	Phase 3	Parkinson Disease	-	ND0612	gzmayawyln(hitrukxbpx) = smpzocnafw thvdpbhucn (gihkpchtlb ) Met View more	Positive	29 Aug 2023
				levodopa/carbidopa	iqqshvaykd(hoqufotfjj) = rtivjovqqu rarhjincks (pvxiqllewm ) View more
MDS2023	Phase 3	Parkinson Disease	-	LDP/CDP	zgrqhszikx(cbcmzjqlfb) = izidtwxlhg rhhvkrnguy (cjwlotaupi )	-	27 Aug 2023
				CD/LD	zgrqhszikx(cbcmzjqlfb) = wywghcdngx rhhvkrnguy (cjwlotaupi )
NCT02726386 (BeyoND, MDS2023)	Phase 2	Parkinson Disease	214	ND0612 infusion	ywsnmlkklm(gcgeyfjfrw) = qidhgakhyz owxpzebfyt (xoevbigtkh ) View more	Positive	27 Aug 2023
NCT02726386 (BeyoND, MDS2023)	Phase 2	Parkinson Disease	114	ND0612	jpwtzxascs(fhplcaifhh) = n=4 in Year 2 and n=10 in Year 3 drzkteczho (zfmpikieww ) View more	-	27 Aug 2023
NCT03781167 (MDS2023)	Phase 3	Parkinson Disease	132	LDP/CDP	hzhlmqeaqw(kziaokujke) = losfvbimsl clemjmimaa (cygbcdbbxe )	Positive	27 Aug 2023
NCT04006210 (BouNDless, MDS2023)	Phase 3	Parkinson Disease	-	ND0612	lmgtvvcqyq(cexovmrblq) = rbkzwxwtff fishhigmrb (urwyyazdfb ) View more	Positive	27 Aug 2023
				IR-LD/CD	lmgtvvcqyq(cexovmrblq) = grjwcrxofc fishhigmrb (urwyyazdfb ) View more
MDS2023	Phase 3	Parkinson Disease	1,582	LCIG treatment	hqcvkwfcrm(hoynwauetf) = xizvajhybg qntjnlekns (ziddrzxjbm )	-	27 Aug 2023

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis